| Title | Cancer Innovation |
| Abbreviation | Cancer Innov. |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Drug Discovery (Q2); Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q2); Oncology (Q3); Pharmacology (medical) (Q3); Cancer Research (Q4) |
| h-index | 7 |
| Overall Rank/Ranking | 10801 |
| SCImago Journal Rank (SJR) | 0.538 |
| Impact Score | 2.07 |
| Publisher | John Wiley and Sons Inc |
| Country | United States |
| ISSN | 27709191, 27709183 |
| Best Quartile | Q2 |
| Coverage History | 2022-2025 |
Cancer Innovation is a journal covering the technologies/fields/categories related to Drug Discovery (Q2); Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q2); Oncology (Q3); Pharmacology (medical) (Q3); Cancer Research (Q4). It is published by John Wiley and Sons Inc. The overall rank of Cancer Innovation is 10801. According to SCImago Journal Rank (SJR), this journal is ranked 0.538. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 7. The best quartile for this journal is Q2.
The ISSN of Cancer Innovation journal is 27709191, 27709183. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Cancer Innovation is cited by a total of 157 articles during the last 3 years (Preceding 2024).
The Impact IF 2024 of Cancer Innovation is 2.07, which is computed in 2025 as per its definition. Cancer Innovation IF is increased by a factor of 0.92 and approximate percentage change is 80% when compared to preceding year 2023, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2024 of Cancer Innovation is 2.07. If the same upward trend persists, Impact IF may rise in 2025 as well.
| Year | Impact IF |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 2.07 |
| 2023 | 1.15 |
Cancer Innovation has an h-index of 7. It means 7 articles of this journal have more than 7 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Cancer Innovation is 27709191, 27709183. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Cancer Innovation is 10801. According to SCImago Journal Rank (SJR), this journal is ranked 0.538. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 0.538 |
| 2023 | 0.389 |
| Year | Ranking |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 10801 |
| 2023 | 13253 |
Cancer Innovation is published by John Wiley and Sons Inc. It's publishing house is located in United States. Coverage history of this journal is as following: 2022-2025. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Cancer Innovation is Cancer Innov.. This abbreviation ('Cancer Innov.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Drug Discovery (Q2); Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q2); Oncology (Q3); Pharmacology (medical) (Q3); Cancer Research (Q4), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Cancer Innovation latest impact IF is 2.07. It's evaluated in the year 2024. The highest and the lowest impact IF or impact score of this journal are 2.07 (2024) and 1.15 (2023), respectively, in the last 2 years. Moreover, its average IS is 1.61 in the previous 2 years.
The Cancer Innovation has an SJR (SCImago Journal Rank) of 0.538, according to the latest data. It is computed in the year 2025. In the past 2 years, this journal has recorded a range of SJR, with the highest being 0.538 in 2024 and the lowest being 0.389 in 2023. Furthermore, the average SJR of the Cancer Innovation over the previous 2-year period stands at 1.61.
The latest h-index of the Cancer Innovation is 7.
The Cancer Innovation is published by the John Wiley and Sons Inc, with its country of publication being the United States.
The Cancer Innovation is currently ranked 10801 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 2 years, this journal has experienced varying rankings, reaching its highest position of 10801 in 2024 and its lowest position of 13253 in 2023.
The standard ISO4 abbreviation for the Cancer Innovation is Cancer Innov..
Cancer Innovation is classified as a journal that the John Wiley and Sons Inc publishes.
The Cancer Innovation encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Cancer Innovation is assigned the following International Standard Serial Numbers (ISSN): 27709191, 27709183.
The best quartile for the Cancer Innovation is Q2 (2024).
The Cancer Innovation coverage history can be summarized as follows: 2022-2025.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Proceedings of the ASME Turbo Expo | conference and proceedings | 17577 | 54 | 0.00 | |
| Analysis in Theory and Applications | journal | 19346 | Springer Netherlands | 11 | 0.00 |
| Journal of Geriatric Physical Therapy | journal | 8686 | Lippincott Williams and Wilkins Ltd. | 53 | 1.55 |
| Journal of Education and Work | journal | 8987 | Brill Academic Publishers | 47 | 2.08 |
| Modern Language Journal | journal | 1033 | Wiley-Blackwell | 123 | 3.95 |
| International Journal of Research and Method in Education | journal | 6367 | Taylor and Francis Ltd. | 41 | 3.31 |
| Transnational Corporations | journal | 13970 | UNCTAD United Nations Conference on Trade and Development | 30 | 1.63 |
| Studies in Continuing Education | journal | 4850 | Routledge | 44 | 3.35 |
| Palaeontographica Abteilung B: Palaeophytologie | book series | 10600 | Schweizerbart Science Publishers | 18 | 4.25 |
| Natural Solutions | trade journal | 28581 | Innovision Health Media | 1 | 0.00 |
| Year | Impact Score (IS) |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 2.07 |
| 2023 | 1.15 |
